Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Luqmani

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
European Journal of Internal Medicine|September 15, 2001
Evaluation of vasculitis disease activity in EuropeR Luqmani
British Journal of Rheumatology|June 1, 1993
The validity of surrogate markers in rheumatic diseaseP Emery, R Luqmani
Annals of the Rheumatic Diseases|October 22, 2005
Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosisC Mukhtyar, R Luqmani
Clinical and Experimental Rheumatology|December 17, 2008
Mortality in systemic vasculitis: a systematic reviewR Phillip, R Luqmani
Clinical and Experimental Rheumatology|November 29, 2007
Disease-specific quality indicators, guidelines, and outcome measures in vasculitisC Mukhtyar, R Luqmani
The British Journal of Clinical Practice|March 1, 1994
Disease-modifying antirheumatic drugs in rheumatoid arthritis: current conceptsP Emery, R Luqmani, C Gordon
Drugs|February 1, 1994
Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid diseaseR Luqmani, C Gordon, P Bacon
British Journal of Rheumatology|February 11, 1999
Outcome in systemic vasculitisR Luqmani, R Moots, L Guillevin
Current Rheumatology Reports|October 12, 2020
Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and FutureB Hellmich, A F Águeda, S Monti, et al.
Eye (London, England)|November 27, 2019
Response to 'Comment on: 'A new era for giant cell arteritis''S P Mollan, V Quick, A J Sinclair, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
European Journal of Internal Medicine|September 15, 2001
Evaluation of vasculitis disease activity in EuropeR Luqmani
British Journal of Rheumatology|June 1, 1993
The validity of surrogate markers in rheumatic diseaseP Emery, R Luqmani
Annals of the Rheumatic Diseases|October 22, 2005
Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosisC Mukhtyar, R Luqmani
Clinical and Experimental Rheumatology|December 17, 2008
Mortality in systemic vasculitis: a systematic reviewR Phillip, R Luqmani
Clinical and Experimental Rheumatology|November 29, 2007
Disease-specific quality indicators, guidelines, and outcome measures in vasculitisC Mukhtyar, R Luqmani
The British Journal of Clinical Practice|March 1, 1994
Disease-modifying antirheumatic drugs in rheumatoid arthritis: current conceptsP Emery, R Luqmani, C Gordon
Drugs|February 1, 1994
Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid diseaseR Luqmani, C Gordon, P Bacon
British Journal of Rheumatology|February 11, 1999
Outcome in systemic vasculitisR Luqmani, R Moots, L Guillevin
Current Rheumatology Reports|October 12, 2020
Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and FutureB Hellmich, A F Águeda, S Monti, et al.
Eye (London, England)|November 27, 2019
Response to 'Comment on: 'A new era for giant cell arteritis''S P Mollan, V Quick, A J Sinclair, et al.
Pageof 4